Augmented myocardial methionine-enkephalin in a murine model of cardiac angiotensin II-overexpression

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 8, Issue 4, 2007, Pages 153-159

  van den Brink, Olivier W V ^a   Durham Delbridge, Lea M ^b   Pedrazzini, Thierry ^c   Rosenfeldt, Franklin L ^a   Pepe, Salvatore ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Angiotensin II; Enkephalin; Hypertrophy mouse; Opioid peptide

Indexed keywords

ANGIOTENSIN II; ENKEPHALIN; METHIONINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE OVEREXPRESSION; GENOTYPE; HEART ATRIUM; HEART VENTRICLE; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; HYPERTENSION; MALE; MOUSE; NONHUMAN; PATHOGENESIS; QUANTITATIVE ANALYSIS; RADIOIMMUNOASSAY; TRANSGENIC MOUSE;

ANGIOTENSIN II; ANIMALS; BODY WEIGHT; ENKEPHALIN, METHIONINE; HEART ATRIA; HEART VENTRICLES; MALE; MICE; MODELS, ANIMAL; MYOCARDIUM; ORGAN SIZE; RATS; STATISTICS, NONPARAMETRIC;

EID: 38649125242     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2007.030     Document Type: Article

References (39)

1. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322:1561-6.
2. Vakili BA, Okin PM, Devereux RB. Prognostic implications of left ventricular hypertrophy. Am Heart J 2001;141;334-41.
3. Frey N, Olson EN. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 2003;65:45-79.
4. Mathew J, Sleight P, Lonn E et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 2001;104:1615-21.
5. Papademetriou V. From hypertension to heart failure. J Clin Hypertens 2004;6:14-17.
6. Dahlof B. Effect of angiotensin II blockade on cardiac hypertrophy and remodelling: a review. J Hum Hypertens 1995;9(Suppl 5):S37-S44.
7. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 2000;52:11-34.
8. Younes A, Pepe S, Barron BA, Spurgeon HA, Lakatta EG, Caffrey JL. Cardiac synthesis, processing, and coronary release of enkephalin-related peptides. Am J Physiol 2000; 279:H1989-98.
9. Holaday JW. Cardiovascular effects of endogenous opiate systems. Annu Rev Pharmacol Toxicol 1983;23:541-94.
10. Springhorn JP, Claycomb WC. Translation of heart preproenkephalin mRNA and secretion of enkephalin peptides from cultured cardiac myocytes. Am J Physiol 1992;263:H1560-H1566.
11. Pepe S, Xiao RP, Hohl C, Altschuld R, Lakatta EG. 'Cross talk' between opioid peptide and adrenergic receptor signaling in isolated rat heart. Circulation 1997;95:2122-9.
12. Xiao RP, Pepe S, Spurgeon HA, Capogrossi MC, Lakatta EG. Opioid peptide receptor stimulation reverses beta-adrenergic effects in rat heart cells. Am J Physiol 1997;272:H797-H805.
13. Pepe S, van den Brink OW, Lakatta EG, Xiao RP. Crosstalk of opioid peptide receptor and beta-adrenergic receptor signalling in the heart. Cardiovasc Res 2004;63:414-22.
14. Younes A, Pepe S, Yoshishige D, Caffrey JL, Lakatta EG. Ischemic preconditioning increases the bioavailability of cardiac enkephalins. Am J Physiol 2005;289:H1652-H1661.
15. Fukuhara M, Matsumura K, Abe I, Fujishima M. Interaction of opioids and vasopressin in central action of angiotensin II in conscious rabbits. Hypertens Res 1998;21:89-95.
16. Takai S, Song K, Tanaka T, Okunishi H, Miyazaki M. Antinociceptive effects of angiotensin-converting enzyme inhibitors and an angiotensin II receptor antagonist in mice. Life Sci 1996; 59:PL331-PL336.
17. Henegar JR, Schwartz DD, Janicki JS. ANG II-related myocardial damage: role of cardiac sympathetic catecholamines and beta-receptor regulation. Am J Physiol 1998;275:H534-H541.
18. Xiang JZ, Linz W, Becker H et al. Effects of converting enzyme inhibitors: ramipril and enalapril on peptide action and sympathetic neurotransmission in the isolated heart. Eur J Pharmacol 1985; 113:215-23.
19. Reid IA. Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. Am J Physiol 1992;262:E763-E&78.
20. Mazzolai L, Nussberger J, Aubert JF et al. Blood pressure-independent cardiac hypertrophy induced by locally activated renin-angiotensin system. Hypertension 1998;31:1324-30.
21. Mazzolai L, Pedrazzini T, Nicoud F, Gabbiani G, Brunner HR, Nussberger J. Increased cardiac angiotensin II levels induce right and left ventricular hypertrophy in normotensive mice. Hypertension 2000; 35:985-91.
22. Domenighetti AA, Wang Q, Egger M, Richards SM, Pedrazzini T, Delbridge LM. Angiotensin II-mediated phenotypic cardiomyocyte remodeling leads to age-dependent cardiac dysfunction and failure. Hypertension 2005;46:426-32.
23. Porrello ER, Huggins CE, Curl CI et al. Elevated dietary sodium intake exacerbates myocardial hypertrophy associated with cardiac-specific overproduction of angiotensin II. JRAAS 2004; 5:169-75.
24. Pellieux C, Aasum E, Larsen TS et al. Overexpression of angiotensinogen in the myocardium induces downregulation of the fatty acid oxidation pathway. J Mol Cell Cardiol 2006;41:459-66.
25. Domenighetti AA, Boixel C, Cefai D, Abriel H, Pedrazzini T. Chronic angiotensin II stimulation in the heart produces an acquired long QT syndrome associated with IK1 potassium current downregulation. J Mol Cell Cardiol 2007;42:63-70.
26. Schunkert H, Sadoshima J, Cornelius T et al. Angiotensin II-induced growth responses in isolated adult rat hearts. Evidence for load-independent induction of cardiac protein synthesis by angiotensin II. Circ Res 1995;76:489-97.
27. Zimmer HG. Catecholamine-induced cardiac hypertrophy: significance of proto-oncogene expression. J Mol Med 1997;75:849-59.
28. Boluyt MO, Younes A, Caffrey JL et al. Age-associated increase in rat cardiac opioid production. Am J Physiol 1993; 265:H212-H218.
29. Caffrey JL, Boluyt MO, Younes A et al. Aging,cardiac proenkephalin mRNA and enkephalin peptides in the Fisher 344 rat. J Mol Cell Cardiol 1994;26:701-11.
30. McLaughlin PJ. Regulation of DNA synthesis of myocardial and epicardial cells in developing rat heart by [Met5]enkephalin. Am J Physiol 1996;271:R122-R129.
31. Zagon IS, Verderame MF, McLaughlin PJ. The biology of the opioid growth factor receptor (OGFr). Brain Res Brain Res Rev 2002; 38:351-76.
32. Pei JM, Wang YM, Zhu YL, Chen M, Wong TM. Signaling pathway mediated by kappa-opioid receptor is impaired in cardiac hypertrophy. Acta Pharmacol Si 2001;22:887-95.
33. Peart JN, Gross GJ. Chronic exposure to morphine produces a marked cardioprotective phenotype in aged mouse hearts. Exp Gerontol 2004;39:1021-6.
34. McLaughlin PJ. Opioid antagonist modulation of rat heart development. Life Sci 1994;54:1423-31.
35. Zagon IS, McLaughlin PJ. Naltrexone modulates growth in infant rats. Life Sci 1983;33:2449-54.
36. Erdos EG, Johnson AR, Boyden NT. Hydrolysis of enkephalin by cultured human endothelial cells and by purified peptidyl dipeptidase. Biochem Pharmacol 1978;27:843-8.
37. Erdos EG, Johnson AR, Boyden NT. Inactivation of enkephalins: effect of purified peptidyl dipeptidase and cultured human endothelial cells. Adv Biochem Psychopharmacol 1978;18:45-9.
38. Skidgel RA, Erdos EG. Angiotensin converting enzyme (ACE) and neprilysin hydrolyze neuropeptides: a brief history, the beginning and follow-ups to early studies. Peptides 2004;25:521-5.
39. SOLVD. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med 1992; 327:685-91.